Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Michael White

Showing results (51-60 of 284) with videos related to

Pageof 29
Sort By:
The Annals of Pharmacotherapy|March 29, 2007
Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutterKrista M Dale, C Michael White
Pharmacy Practice|April 25, 2019
The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trialsC Michael White, Ji-Young Lee
Journal of Clinical Pharmacology|August 16, 2021
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and SelankCassandra R Doyno, C Michael White
Pharmacotherapy|August 19, 2003
Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic managementBrian F McBride, C Michael White
The Annals of Pharmacotherapy|March 21, 2018
The Emerging Role of Inflammation in Cardiovascular DiseaseBrandon K Martinez, C Michael White
Journal of Clinical Pharmacology|December 17, 2004
Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMETBrian F McBride, C Michael White
Journal of Clinical Pharmacology|December 2, 2021
Response to Letter to the Editor by Dr RobinsonC Michael White, Lyla R White
Journal of Clinical Pharmacology|March 13, 2022
Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein ReductionKimberly W Smith, C Michael White
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 7, 2009
Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromesWilliam L Baker, C Michael White
Connecticut Medicine|January 21, 2003
Monitoring antifactor Xa activity of the low-molecular-weight heparins in the clinical setting: who, why, how, and when?James S Kalus, C Michael White
Pageof 29

Showing results (51-60 of 284) with videos related to

Sort By:
Pageof 29
The Annals of Pharmacotherapy|March 29, 2007
Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutterKrista M Dale, C Michael White
Pharmacy Practice|April 25, 2019
The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trialsC Michael White, Ji-Young Lee
Journal of Clinical Pharmacology|August 16, 2021
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and SelankCassandra R Doyno, C Michael White
Pharmacotherapy|August 19, 2003
Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic managementBrian F McBride, C Michael White
The Annals of Pharmacotherapy|March 21, 2018
The Emerging Role of Inflammation in Cardiovascular DiseaseBrandon K Martinez, C Michael White
Journal of Clinical Pharmacology|December 17, 2004
Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMETBrian F McBride, C Michael White
Journal of Clinical Pharmacology|December 2, 2021
Response to Letter to the Editor by Dr RobinsonC Michael White, Lyla R White
Journal of Clinical Pharmacology|March 13, 2022
Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein ReductionKimberly W Smith, C Michael White
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 7, 2009
Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromesWilliam L Baker, C Michael White
Connecticut Medicine|January 21, 2003
Monitoring antifactor Xa activity of the low-molecular-weight heparins in the clinical setting: who, why, how, and when?James S Kalus, C Michael White
Pageof 29